Blog
About

690
views
0
recommends
+1 Recommend
0 collections
    31
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sorafenib in advanced hepatocellular carcinoma.

      The New England journal of medicine

      Aged, antagonists & inhibitors, raf Kinases, Survival Analysis, therapeutic use, adverse effects, Pyridines, Protein Kinase Inhibitors, Proportional Hazards Models, Phenylurea Compounds, analogs & derivatives, Niacinamide, Neoplasm Staging, Middle Aged, Benzenesulfonates, Male, surgery, mortality, drug therapy, Liver Neoplasms, Humans, Female, Double-Blind Method, Disease Progression, Chemotherapy, Adjuvant, Carcinoma, Hepatocellular

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.) 2008 Massachusetts Medical Society

          Related collections

          Author and article information

          Journal
          18650514
          10.1056/NEJMoa0708857

          Comments

          Comment on this article